

**REMARKS**

Applicants present this amendment in response to the Examiner initiated telephone interview with Applicants' representatives Michael Siekman and Marie Aucoin. Applicants have amended the specification as requested to renumber the Tables consecutively as they appear in the text. Applicants have amended the Tables to reflect the amended Table numbers. Applicants have inserted Table 220 (now Table 21) and Table 221 (now Table 22) from U.S. Patent No. 5,663,143 which is incorporated by reference. Support for this insertion is found on page 1, lines 21-22 and page 21, lines 11-14. Applicants have added the sequence identifiers for each of the sequences in Table 5 (formerly Table 13) and corrected the sequence identifiers for the sequences in Tables 12-13 (formerly Tables 207-208). Support is found in the sequence listing. In the paragraphs that originally contained underlined text, Applicants have used double-underlining to distinguish the added text from the original text. No new matter has been added.

The Examiner also indicated the priority claims for this application was confusing. As Applicants' representatives discussed with the Examiner, Applicants have amended the application to clearly claim priority back to Application Serial No. US 08/133,031.

Applicants submit herewith a substitute sequence listing to replace the sequence listing submitted June 7, 2002. As discussed with Examiner Moore on March 16, 2005, Applicants have corrected the original sequence list in the following way. The title was corrected to correct a typographical error ("nHE" was replaced with "HNE") and the docket number updated to reflect our docket number. The priority information was updated to reflect the corresponding priority information in the amended paragraph of the specification. A typographical error in SEQ ID NOs:1 and 2 was corrected ("mautre" was replaced with "mature"). The eleven sequences disclosed in the specification that were not included in the original sequence list were added and the corresponding paragraphs updated to include the sequence identifiers. SEQ ID NOs:103, 104, 106, 109 and 123 were corrected to replace "Glx" at residue 1 with Xaa, wherein Xaa is Glu or Gln. Support for this is found in Table 5 (formerly Table 13) wherein the first amino acid residue is disclosed as "z" which represents Glu or Gln (see MPEP § 2422, Table 1). SEQ ID NOs:82 and 84 were corrected to include each of the undefined nucleotide residues, for

example residue 38 in SEQ ID NO:82 is disclosed as “r” which represents adenine or guanine (see MPEP § 2422, Table 1). Support for this is found in the specification on page 127.

As the Examiner requested, Applicants file herewith a Terminal Disclaimer over U.S. Patent No. 5,663,143.


**CONCLUSION**

Applicants believe this amendment puts the claims in condition for allowance. A Notice of Allowance is respectfully requested. The Examiner is requested to call the undersigned at the telephone number listed below if this communication does not place the case in condition for allowance to resolve an remaining issues.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,  
*Arthur C. Ley et al., Applicant(s)*

By:



Michael T. Siekman, Reg. No. 36,276  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: D0617.70005US01  
Date: March 17, 2005  
**xxNDDxx**